PolyPid Ltd.
PolyPid Ltd. is a U.S.-listed biopharmaceutical company that develops long-acting, controlled-release therapies designed to deliver drugs locally at the site of care. Its pipeline spans surgical care and metabolic diseases, with D-PLEX100 as its lead product candidate for preventing surgical site infections.
Business
Share of revenueD-PLEX100 and related surgical-care applications designed to prevent infections at the surgical site.
Long-acting, controlled-release formulations that release therapy locally at the site of care.
Programs aimed at reducing complications and improving outcomes in surgical settings.
Development-stage programs beyond surgery, including metabolic disease applications.
Customers
PolyPid's primary end users are hospitals, surgeons, and healthcare systems that need therapies to reduce surgical site infections and improve perioperative outcomes. In addition, its product development is relevant to pharmaceutical and healthcare partners that may support clinical development, commercialization, or distribution. Because the company is still clinical-stage, customer demand is tied more to adoption by medical professionals and institutional purchasing decisions than to traditional consumer buying.
They would buy D-PLEX100 or similar products to help prevent surgical site infections and improve clinical outcomes.
They influence adoption by selecting therapies used around surgery when infection prevention is a clinical priority.
They evaluate therapies based on clinical benefit, complication avoidance, and overall treatment value.
They may support late-stage development, manufacturing, or distribution of pipeline products.
Strategy
PolyPid's strategy is centered on advancing D-PLEX100 and building evidence that its local delivery platform improves surgical outcomes. More broadly, the company is extending its controlled-release technology into additional therapeutic areas, including metabolic diseases, to expand the pipeline and diversify future opportunities. Clinical execution, regulatory milestones, and future commercialization planning are central to its competitive position.
The lead program is the core asset and the main path to clinical validation and eventual commercialization.
Additional programs reduce dependence on one asset and broaden the platform's commercial relevance.
A successful launch requires manufacturing, distribution, and adoption planning beyond clinical development.
Geography
PolyPid is incorporated and listed in the United States, but its reported business is global in scope because its drug candidates are intended for international healthcare markets. The company also maintains operations and corporate activity outside the U.S., and its clinical and commercialization pathway may depend on approvals and adoption across multiple jurisdictions. As a development-stage biotech, geography matters mainly through trial execution, regulatory pathways, and eventual market access rather than current sales concentration.
Risks
PolyPid faces typical biotech risks tied to clinical development, regulatory review, and the ability to translate trial success into commercial uptake. Because it is focused on a lead asset and a developing pipeline, setbacks in efficacy, safety, manufacturing, or reimbursement could have outsized impact on the business. Funding needs, dilution risk, and execution risk also remain important until the company generates durable product revenue.
- Clinical development riskImpact: CriticalLikelihood: Medium
The company's value depends heavily on successful clinical outcomes for D-PLEX100 and other programs.
Exposure: Lead product and pipeline
- Financing and dilution riskImpact: HighLikelihood: High
As a clinical-stage biotech, the company may need external capital before meaningful product revenue.
Exposure: Cash burn and development spend
- Regulatory approval riskImpact: HighLikelihood: Medium
Positive trial data does not guarantee approval, labeling, or timely commercialization.
Exposure: Surgical infection prevention therapy
- Commercial adoption riskImpact: HighLikelihood: Medium
Hospitals and surgeons must change practice patterns and justify adoption economically.
Exposure: D-PLEX100 launch potential
- Manufacturing and scale-up riskImpact: MediumLikelihood: Medium
Controlled-release therapies can require specialized production and quality controls.
Exposure: Product launch and supply chain
Accounting
Judgemental itemsThe company discloses estimates for financial assets and liabilities that depend on market and model assumptions.
Impact: Can move reported expenses or gains/losses
Option and equity awards require valuation assumptions that affect operating expense.
Impact: Influences reported loss and dilution analysis
Inventory held before commercialization may require valuation review if launch is delayed or demand is uncertain.
Impact: Possible write-downs or margin effects later
Development-stage costs and milestone timing can make quarterly results uneven and hard to compare.
Impact: Affects trend interpretation across quarters
Similar listed companies
Publicly listed companies with a comparable business focus.
Palisade Bio, Inc
PALI · Biological Products, (No Diagnostic Substances)
Dyadic International, Inc
DYAI · Biological Products, (No Diagnostic Substances)
Dyadic International is a U.S.-based biotechnology platform company that develops microbial protein production systems for industrial, life sciences, food and…
Ligand Pharmaceuticals Incorporated
LGND · Pharmaceutical Preparations
Ligand Pharmaceuticals is a biopharmaceutical royalty company that acquires, finances, and licenses rights to high-value medicines rather than developing drugs itself.
POMDOCTOR Ltd
POM · Retail-Miscellaneous Retail
POMDOCTOR Ltd is a China-based digital healthcare company built around an internet hospital platform, physician network, and pharmaceutical supply chain operations.
Advanced Biomed Inc.
ADVB · Services-Medical Laboratories
Calidi Biotherapeutics, Inc.
CLDWW · Biological Products, (No Diagnostic Substances)
Last updated: 28/09/2026